

Japan Contract Development And Manufacturing Organization Market By Product (API, Drug Product), By Workflow (Clinical, Commercial), By Application (Oncology, Hormonal, Glaucoma, Cardiovascular Disease, Diabetes, Others), By Region, By Competition Forecast & Opportunities, 2020-2030F

<https://marketpublishers.com/r/J19CA767D149EN.html>

Date: April 2024

Pages: 84

Price: US\$ 3,500.00 (Single User License)

ID: J19CA767D149EN

Abstracts

Japan Contract Development And Manufacturing Organization Market was valued at USD 11.68 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.41% through 2030. The surging need for biopharmaceuticals, a substantial disease burden, and the increasing elderly population constitute prominent factors propelling growth in this industry. Additionally, various contract development and manufacturing organizations (CDMOs) are augmenting their investments to expand their facilities and services.

Key Market Drivers

Growing Pharmaceutical Market

Japan's Contract Development and Manufacturing Organization (CDMO) market is experiencing notable growth, driven by the expansion of the country's pharmaceutical sector. With Japan's pharmaceutical market on the rise, CDMOs are strategically positioned to capitalize on this trend and play a crucial role in meeting the growing demand for drug development and manufacturing services.

The burgeoning pharmaceutical market in Japan has led to increased outsourcing by pharmaceutical companies. Faced with the need to address healthcare challenges amid

an aging population and prevalent diseases, these companies are turning to CDMOs for their specialized expertise and resources. By outsourcing complex processes like drug development and manufacturing, pharmaceutical firms can focus on their core competencies, optimize resource allocation, and expedite the overall drug development timeline. CDMOs, equipped with experienced teams and advanced facilities, are instrumental in accelerating drug development efforts. They provide pharmaceutical companies with a turnkey solution, minimizing the time and resources required to establish in-house capabilities. Additionally, outsourcing to CDMOs offers cost-effective benefits by avoiding hefty capital expenditures associated with internal development and manufacturing infrastructure.

Also, CDMOs invest heavily in cutting-edge technologies and adhere to industry best practices. Collaborating with CDMOs grants pharmaceutical companies access to these advanced technologies and expertise, resulting in higher-quality products and faster time-to-market for new drugs. Moreover, CDMOs possess in-depth knowledge of Japan's stringent regulatory requirements, ensuring compliance throughout the drug development and manufacturing processes. This expertise is invaluable for pharmaceutical companies navigating the complex regulatory landscape and seeking approval for their products.

Regulatory Advancements

Japan's Contract Development and Manufacturing Organization (CDMO) market is undergoing a significant transformation, primarily driven by regulatory changes that have reshaped the landscape for pharmaceutical development and production.

A notable regulatory advancement in Japan is the streamlining of the drug approval process. Previously, obtaining approval for new pharmaceuticals in Japan was a complex and time-consuming endeavor. However, recent regulatory reforms have expedited this process, resulting in shortened timelines for regulatory approvals and quicker market entry for new drugs. This has directly impacted the CDMO industry, as pharmaceutical companies seek partners capable of efficiently bringing their products to market. Regulatory changes have made it easier for foreign pharmaceutical companies to conduct clinical trials in Japan. This has attracted global pharmaceutical players to consider Japan for their clinical research activities, leading to increased reliance on local CDMOs to provide the necessary infrastructure and expertise. As a result, the demand for CDMO services has surged, solidifying Japan's position as a hub for clinical research.

Also, regulatory flexibility now allows pharmaceutical companies to manufacture their products within Japan, paving the way for increased collaboration with CDMOs for manufacturing services. This regulatory alignment with international standards has encouraged greater collaboration in drug development and manufacturing, with Japanese CDMOs positioned as preferred partners due to their expertise in navigating regulatory complexities. The regulatory environment has fostered a culture of innovation by reducing the burden for novel therapies and treatments. Pharmaceutical companies are now more inclined to explore new avenues in drug development, with CDMOs playing a pivotal role in facilitating this process. Leveraging their specialized knowledge, infrastructure, and resources, CDMOs accelerate the development and production of innovative pharmaceuticals.

Investments in RD

Japan's Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth, fueled by substantial investments in Research and Development (RD).

RD investments are pivotal for driving innovation in the pharmaceutical and biotechnology sectors. Japan's robust commitment to RD has led to groundbreaking advancements in drug development and production. Pharmaceutical companies, aiming to maintain their competitive edge in healthcare, partner with CDMOs to tap into the knowledge and expertise essential for pioneering research. This collaboration fosters innovation in drug development and manufacturing, expanding the CDMO market's scope. These investments in RD expedite pharmaceutical development. With ample financial backing and research support, pharmaceutical firms can efficiently progress their drug candidates. CDMOs facilitate this process by providing specialized services, cutting-edge facilities, and seasoned teams dedicated to accelerating drug development. This acceleration translates to shorter time-to-market, a highly appealing prospect for pharmaceutical companies, and a boon for CDMOs.

Also, RD investments empower CDMOs to diversify and enhance their service offerings. As CDMOs gain deeper insights into the evolving pharmaceutical landscape, they adapt their capabilities to meet industry demands. This adaptability is instrumental in the CDMO market's growth, allowing these organizations to offer a comprehensive suite of services tailored to pharmaceutical companies' specific needs. RD investments also enable CDMOs to develop specialized expertise in various facets of pharmaceutical development and manufacturing. This expertise is invaluable to pharmaceutical companies seeking partners with in-depth knowledge and guidance in areas like

biologics, small molecule drugs, and advanced therapies. CDMOs with a proven track record of innovation are highly sought after and can capture a significant market share.

Japanese CDMOs, supported by substantial RD investments, are increasingly attractive partners for international pharmaceutical companies. Collaborations in global RD initiatives enable CDMOs to participate in drug development projects with worldwide reach. This not only drives their growth but also elevates Japan's reputation as a hub for pharmaceutical innovation and manufacturing. With increased RD investments, CDMOs have the financial means to acquire and implement advanced technologies. This allows them to offer cutting-edge solutions for drug development and manufacturing. Pharmaceutical companies striving to remain industry leaders are eager to collaborate with CDMOs providing the latest technology and expertise.

Focus on Advanced Therapies

Japan's Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth, driven by a substantial focus on advanced therapies.

The pharmaceutical and biotech sectors are witnessing a rapid evolution, with a growing emphasis on advanced therapies like cell and gene therapies. These therapies hold immense promise for addressing complex and previously untreatable diseases. As the demand for healthcare innovation rises, pharmaceutical firms are increasingly partnering with CDMOs to leverage their specialized expertise and cutting-edge facilities in developing advanced therapies.

Advanced therapies, such as gene editing and cell-based treatments, are highly complex and demand specialized knowledge and infrastructure. Japanese CDMOs, committed to fostering innovation, have made significant investments in the expertise and facilities required to support the development and manufacturing of these therapies. This expertise positions them as invaluable partners for pharmaceutical companies seeking to bring groundbreaking treatments to market. Japan's focus on advanced therapies has led to a surge in clinical trials for these treatments within the country. CDMOs, with their experience in navigating regulatory frameworks and conducting clinical research, play a vital role in supporting these trials. Their ability to efficiently manage clinical trial logistics and manufacturing for advanced therapies expedites the drug development process, making CDMOs indispensable in this regard.

As the demand for advanced therapies continues to rise, Japanese CDMOs are heavily investing in expanding their facilities and capabilities. They are equipped to develop and

manufacture these therapies at scale, meeting the requirements of pharmaceutical companies aiming to introduce innovative treatments to a wider patient base. Japan's emphasis on advanced therapies has garnered the attention of international pharmaceutical firms. These firms are increasingly collaborating with Japanese CDMOs due to their expertise in advanced therapy development and manufacturing. This global collaboration contributes to the growth of Japan's CDMO market, positioning the country as a key player in advancing cutting-edge therapies.

Key Market Challenges

Competition and Market Saturation

The CDMO market in Japan is becoming increasingly competitive, with both domestic and international players vying for market share. This competition can lead to pricing pressures and the need for CDMOs to distinguish themselves through innovation and specialization. In such a crowded market, smaller CDMOs may find it challenging to thrive.

Quality Control and Consistency

Maintaining consistent quality in pharmaceutical manufacturing is paramount. However, ensuring that processes meet the highest international standards is an ongoing challenge. CDMOs in Japan need to invest heavily in quality control and operational excellence to retain their competitive edge and satisfy the stringent demands of pharmaceutical companies.

Intellectual Property Concerns

Intellectual property concerns can pose challenges for CDMOs in Japan. Protecting the intellectual property of pharmaceutical companies is critical, and the CDMOs must adhere to stringent confidentiality and security protocols. Adhering to these requirements, while also collaborating effectively, is a delicate balancing act.

Key Market Trends

Advanced Therapies Dominance

One of the most pronounced trends in Japan's CDMO market is the increasing dominance of advanced therapies, particularly cell and gene therapies. These

groundbreaking treatments represent the future of medicine, offering novel solutions for previously untreatable diseases. Japanese CDMOs are likely to expand their capabilities to cater to the growing demand for advanced therapies, including investing in state-of-the-art facilities and specialized expertise.

Strategic Partnerships

Strategic collaborations between CDMOs and pharmaceutical companies are expected to become even more prevalent. These partnerships offer pharmaceutical firms access to specialized expertise and infrastructure while allowing CDMOs to expand their service offerings and global reach. Joint ventures and long-term partnerships are likely to be a hallmark of the CDMO market's evolution.

Global Expansion

Many Japanese CDMOs are pursuing international expansion to tap into the growing global demand for pharmaceutical manufacturing services. This trend is expected to continue, with Japanese CDMOs establishing a strong global presence and attracting international pharmaceutical companies seeking reliable partners.

Segmental Insights

Product Insights

In 2024, the API sector secured the largest portion of revenue and is projected to exhibit the most rapid CAGR throughout the forecast period. The segment's growth is underpinned by a rising demand for new pharmaceuticals in Japan and the significant prevalence of diseases in the country. Furthermore, government initiatives to promote the adoption of generic medications and the ongoing expansion of facilities by industry players are also contributing to the segment's expansion.

Regional Insights

The Chubu region is positioned to exert a dominant influence on the Contract Development and Manufacturing Organization (CDMO) market in Japan for several compelling reasons. Firstly, Chubu boasts a robust pharmaceutical ecosystem with a high concentration of pharmaceutical companies and research institutions, providing a fertile ground for CDMO activities. Furthermore, its strategic location in central Japan makes it easily accessible and well-connected to major cities, ensuring efficient

logistical support for CDMO services. Additionally, Chubu's commitment to innovation and its investment in cutting-edge technology and infrastructure underscore its competitiveness in the CDMO sector. As a region characterized by a skilled workforce and a proactive approach to regulatory compliance, Chubu is well-poised to meet the growing demands of pharmaceutical companies for high-quality contract development and manufacturing services, ultimately solidifying its dominance in the Japanese CDMO market.

Key Market Players

CordenPharma International (JAPAN)

WuXi AppTec Inc

Cambrex Corp

Recipharm AB

Lonza Group AG

Catalent Inc

Laboratory Corporation of America Holdings

Thermo Fisher Scientific Inc

Samsung Biologics Co Ltd

Fujifilm Corp

Report Scope:

In this report, the Japan Contract Development And Manufacturing Organization Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Japan Contract Development And Manufacturing Organization Market,By Product:

oAPI

oDrug Product

Japan Contract Development And Manufacturing Organization Market,By Workflow:

oClinical

oCommercial

Japan Contract Development And Manufacturing Organization Market, By Application:

oOncology

oHormonal

oGlaucoma

oCardiovascular Disease

oDiabetes

oOthers

Japan Contract Development And Manufacturing Organization Market, By Region:

oChubu

oChugoku

oKyushu

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Japan Contract Development And Manufacturing Organization Market.

Available Customizations:

Japan Contract Development And Manufacturing Organization marketreport with the

Japan Contract Development And Manufacturing Organization Market By Product (API, Drug Product), By Workflow (...)

given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1.SERVICE OVERVIEW

- 1.1.Market Definition
- 1.2.Scope of the Market
 - 1.2.1.Markets Covered
 - 1.2.2.Years Considered for Study
 - 1.2.3.Key Market Segmentations

2.RESEARCH METHODOLOGY

- 2.1.Objective of the Study
- 2.2.Baseline Methodology
- 2.3.Key Industry Partners
- 2.4.Major Association and Secondary Sources
- 2.5.Forecasting Methodology
- 2.6.Data Triangulation Validations
- 2.7.Assumptions and Limitations

3.EXECUTIVE SUMMARY

- 3.1.Overview of the Market
- 3.2.Overview of Key Market Segmentations
- 3.3.Overview of Key Market Players
- 3.4.Overview of Key Regions/Countries
- 3.5.Overview of Market Drivers, Challenges, Trends

4.VOICE OF CUSTOMER

5.JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET OUTLOOK

- 5.1.Market Size Forecast
 - 5.1.1.By Value
- 5.2.Market Share Forecast
 - 5.2.1.By Product (API, Drug Product)
 - 5.2.2.By Workflow (Clinical, Commercial)
 - 5.2.3.By Application (Oncology, Hormonal, Glaucoma, Cardiovascular Disease,

Diabetes, Others)

5.2.4.By Region

5.2.5.By Company (2024)

5.3.Market Map

6.CHUBU CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET OUTLOOK

6.1.Market Size Forecast

6.1.1.By Value

6.2.Market Share Forecast

6.2.1.By Product

6.2.2.By Workflow

6.2.3.By Application

7.KYUSHU CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET OUTLOOK

7.1.Market Size Forecast

7.1.1.By Value

7.2.Market Share Forecast

7.2.1.By Product

7.2.2.By Workflow

7.2.3.By Application

8.CHUGOKU CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET OUTLOOK

8.1.Market Size Forecast

8.1.1.By Value

8.2.Market Share Forecast

8.2.1.By Product

8.2.2.By Workflow

8.2.3.By Application

9.MARKET DYNAMICS

9.1.Drivers

9.2.Challenges

10.MARKET TRENDS DEVELOPMENTS

- 10.1.Recent Development
- 10.2.Mergers Acquisitions
- 10.3.Product Launches

11.JAPAN CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: SWOT ANALYSIS

12.PORTER'S FIVE FORCES ANALYSIS

- 12.1.Competition in the Industry
- 12.2.Potential of New Entrants
- 12.3.Power of Suppliers
- 12.4.Power of Customers
- 12.5.Threat of Substitute Products

13.COMPETITIVE LANDSCAPE

- 13.1.Corden Pharma International (JAPAN)
 - 13.1.1.Service Overview
 - 13.1.2.Product Offerings
 - 13.1.3.Recent Developments
 - 13.1.4.Key Personnel
 - 13.1.5.SWOT Analysis
- 13.2.WuXi AppTec Inc
- 13.3.Cambrex Corp
- 13.4.Recipharm AB
- 13.5.Lonza Group AG
- 13.6.Catalent Inc
- 13.7.Laboratory Corporation of America Holdings
- 13.8.Thermo Fisher Scientific Inc
- 13.9.Samsung Biologics Co Ltd
- 13.10.Fujifilm Corp

14.STRATEGIC RECOMMENDATIONS

15.ABOUT US DISCLAIMER

I would like to order

Product name: Japan Contract Development And Manufacturing Organization Market By Product (API, Drug Product), By Workflow (Clinical, Commercial), By Application (Oncology, Hormonal, Glaucoma, Cardiovascular Disease, Diabetes, Others), By Region, By Competition Forecast & Opportunities, 2020-2030F

Product link: <https://marketpublishers.com/r/J19CA767D149EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/J19CA767D149EN.html>